Iatrogenic antibody deficiency from B-cell targeted therapies in autoimmune rheumatic diseases

B-cell targeted therapies (BCTT) are now widely used in autoimmune rheumatic diseases, including SLE, antineutrophil cytoplasmic antibody-associated vasculitis and rheumatoid arthritis. Early studies suggested that rituximab did not influence serum immunoglobulins. However, subsequently, with increa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wijetilleka, Sonali, Jayne, David, Mukhtyar, Chetan, Karim, Mohammed Yousuf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667775/
https://www.ncbi.nlm.nih.gov/pubmed/31413852
http://dx.doi.org/10.1136/lupus-2019-000337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667775/
https://www.ncbi.nlm.nih.gov/pubmed/31413852
http://dx.doi.org/10.1136/lupus-2019-000337

Ejemplares similares